Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia

Brain

Volumn 121, Issue 3, 1998, Pages 527-533

  Rascol, O ^a,c   Sabatini, U ^a,b   Brefel, C ^a   Fabre, N ^a   Rai, S ^a   Senard, J M ^a   Celsis, P ^a   Viallard, G ^a   Montastruc, J L ^a   Chollet, F ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Abnormal involuntary movements; Parkinson's disease; Peak dose dyskinesia; rCBF; Single photon emission tomography

Indexed keywords

LEVODOPA; XENON 133;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; DYSKINESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR CORTEX; MOTOR PERFORMANCE; PARKINSON DISEASE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0031882302     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/121.3.527     Document Type: Article

References (32)

1. Adler LE, Pecevich M, Nagamoto H. Bereitschaftspotential in tardive dyskinesia. Mov Disord 1989; 4: 105-12.
2. Agid Y, Bonnet AM, Ruberg M, Javoy-Agid F. Pathophysiology of L-dopa induced abnormal involuntary movements. In: Casey DE, Chase TN, Christensen AV, Gerlach J, editors. Dyskinesia: research and treatment. Berlin: Springer Verlag; 1985. pp. 145-59.
3. Barbeau A. L-dopa therapy in Parkinson's disease. A critical review of nine years experience. [Review]. Can Med Assoc J 1969; 101: 59-68.
4. Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates [published erratum appears in Trends Neurosci 1991; 14: 119]. [Review]. Trends Neurosci 1991; 14: 21-7.
5. Ceballos-Baumann AO, Passingham RE, Warner T, Playford ED, Marsden CD, Brooks DJ. Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia: a PET activation study. Ann Neurol 1995a; 37: 363-72.
6. Ceballos-Baumann AO, Passingham RE, Marsden CD, Brooks DJ. Motor reorganization in acquired hemidystonia. Ann Neurol 1995b; 37: 746-57.
7. Cedarbaum JM, Gandy SE, McDowell FH. 'Early' initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991; 41: 622-9.
8. Celsis P, Goldman T, Henriksen L, Lassen NA. A method for calculating regional cerebral blood flow from emission computed tomography of inert gas concentrations. J Comput Assist Tomogr 1981; 5: 641-5.
9. Chase TN, Holden EM, Brody JA. Levodopa-induced dyskinesias. Comparison in parkinsonism-dementia and amyotrophic lateral sclerosis. Arch Neurol 1973; 29: 328-33.
10. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280: 337-45.
11. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. [Review]. Mov Disord 1990; 5: 100-8.
12. DeLong MR. Primate models of movement disorders of basal ganglia origin. [Review]. Trends Neurosci 1990; 13: 281-5.
13. Fahn S, Elton R and the members of the Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, editors. Recent developments in Parkinson's disease. New York: MacMillan, 1987. pp. 153-63.
14. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. [Review]. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
15. Hoehn MM, Yahr MD. Parkinsonism: onset progression and mortality. Neurology 1967; 17: 427-42.
16. Horstink MW, Zijlmans JC, Pasman JW, Berger HJ, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990; 53: 224-6.
17. Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992; 32: 749-57.
18. Leenders KL, Wolfson L, Gibbs JM, Wise RJ, Causon R, Jones T, et al. The effects of L-dopa on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 1985; 108: 171-91.
19. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12.
20. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific; 1982. pp. 96-122.
21. Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, et al. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990; 5: 49-54.
22. Montastruc JL, Celsis P, Agniel A, Demonet JF, Doyon B, Puel M, et al. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements. Mov Disord 1987; 2: 279-89.
23. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. [Review]. Neurology 1990; 40: 340-5.
24. Piccini P, Boecker H, Weeks RA, Brooks DJ. Dyskinesia correlated regional blood flow changes in Parkinson's disease [abstract]. Neurology 1997; 48 (3 Suppl): A327.
25. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992; 32: 151-61.
26. Rascol O, Sabatini U, Chollet F, Celsis P, Montastruc JL, Marc-Vergnes JP, et al. Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol 1992; 49: 144-8.
27. Rascol O, Sabatini U, Chollet F, Fabre N, Senard JM, Montastruc JL, et al. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry 1994; 57: 567-71.
28. Rascol O, Sabatini U, Fabre N, Brefel C, Loubinoux I, Celsis P, et al. The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain 1997; 120: 103-10.
29. Sabatini U, Rascol O, Celsis P, Houin G, Rascol A, Marc-Vergnes JP, et al. Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms. Br J Clin Pharmacol 1991; 32: 229-34.
30. Sabatini U, Chollet F, Rascol O, Celsis P, Rascol A, Lenzi GL, et al. Effect of side and rate of stimulation on cerebral blood flow changes in motor areas during finger movements in humans. J Cereb Blood Flow Metab 1993; 13: 639-45.
31. Samuel M, Ceballos-Baumann AO, Blin J, Uema T, Boecker H, Passingham RE, et al. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study. Brain 1997; 120: 963-76.
32. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin, and their metabolites in Parkinson's disease. Brain Res 1983; 275: 321-28.